Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 28Lymphoma, Mantle-Cell 19Lymphoma, Large B-Cell, Diffuse 16Lymphoma, Follicular 10Waldenstrom Macroglobulinemia 9Lymphoma, B-Cell, Marginal Zone 9Lymphoma, Non-Hodgkin 8Neoplasms 7Lymphoma 7Recurrence 5Lymphoma, B-Cell 5Multiple Myeloma 4Burkitt Lymphoma 4Leukemia, Myeloid, Acute 3Leukemia, Lymphoid 3Leukemia, B-Cell 3Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Leukemia, Prolymphocytic, B-Cell 2Glioblastoma 2Brain Neoplasms 2Prostatic Neoplasms, Castration-Resistant 1Primary Central Nervous System Lymphoma (PCNSL) 1Neuroectodermal Tumors, Primitive 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Multi-centric Castleman's Disease 1Monoclonal Gammopathy of Undetermined Significance 1Melanoma 1

Interventions

Rosuvastatin Calcium 5capivasertib 2Digoxin 2sotorasib 1ibrutinib 1Midazolam 1Dextromethorphan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Healthy Participants × ibrutinib × Clear all
NCT01674322 2014-11-05

A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants

Janssen Research & Development, LLC

Phase 1 Completed
6 enrolled

Healthy Participants

Data powered by HemOnc (CC BY 4.0) Colophon âš¡